Orencia abatacept: Interim Phase IIb/III data

Bristol-Myers Squibb Co. (BMY), New York, N.Y.
Product: Orencia abatacept
Business: Autoimmune
Molecular target: CD80 (B7-1); CD86 (B7-2)
Description:

Read the full 190 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE